RXi Pharmaceuticals’ (RXII) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of RXi Pharmaceuticals (NASDAQ:RXII) in a research report released on Monday.

“Valuation, risks and uncertainties. We value RXi’s entire portfolio at $100M, with $30M from the RNAi platform for I/O uses and the remaining $70M from additional development-stage candidates, including RXI-109 and Samcyprone, which we expect to bring in further revenue from out-licensing efforts.”,” HC Wainwright’s analyst commented.

Separately, ValuEngine upgraded shares of RXi Pharmaceuticals from a hold rating to a buy rating in a research report on Thursday, August 2nd.

NASDAQ RXII opened at $0.44 on Monday. RXi Pharmaceuticals has a 12 month low of $0.40 and a 12 month high of $7.70.

RXi Pharmaceuticals (NASDAQ:RXII) last posted its quarterly earnings data on Tuesday, August 14th. The biotechnology company reported ($0.46) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.62) by $0.16. The company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.02 million. Analysts expect that RXi Pharmaceuticals will post -1.55 earnings per share for the current year.

A hedge fund recently bought a new stake in RXi Pharmaceuticals stock. SG Americas Securities LLC purchased a new position in RXi Pharmaceuticals Corp (NASDAQ:RXII) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 118,387 shares of the biotechnology company’s stock, valued at approximately $228,000. SG Americas Securities LLC owned about 2.78% of RXi Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 8.87% of the company’s stock.

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.

Further Reading: Risk Tolerance

Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply